Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.54 |
| ▸ | CHRNG | P07510 | 1/20 | 0.54 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.54 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8593124 | 0.87 | NPSR1 (0.69) | HPGDNPSR1LMNAKMT2AATM | |
| SCHEMBL13753410 | 0.86 | HPGD (0.62) | HPGDNPC1RAB9ALMNAGPR139 | |
| SCHEMBL7399516 | 0.85 | HPGD (0.66) | HPGDNPC1RAB9ALMNAPOLB | |
| SCHEMBL2159492 | 0.85 | HPGD (0.61) | HPGDNPC1RAB9ALMNAGPR139 | |
| SCHEMBL5747070 | 0.85 | HPGD (0.61) | HPGDNPC1RAB9ALMNAGPR139 | |
| SCHEMBL13753580 | 0.83 | HPGD (0.72) | HPGDNPC1RAB9ALMNAGPR139 | |
| SCHEMBL22151090 | 0.83 | HPGD (0.59) | HPGDNPC1RAB9ALMNAGPR139 | |
| SCHEMBL8802537 | 0.83 | HPGD (0.59) | HPGDNPC1RAB9ALMNAGPR139 | |
| SCHEMBL8737626 | 0.83 | HPGD (0.72) | HPGDNPC1RAB9ALMNAGPR139 | |
| SCHEMBL13753670 | 0.83 | HPGD (1.00) | HPGDNPC1RAB9ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11858879-B2 | PARG inhibitors and method of use thereof | CITY OF HOPE (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858879-B2 | PARG inhibitors and method of use thereof | CITY OF HOPE (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3694502-B1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220002231-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | CITY OF HOPE | 2022-01-06 | — | — | US | disclosed |
| US-11111232-B2 | Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-09-07 | — | — | US | disclosed |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-7354919-B2 | Isoxazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20070031514-A1 | Use of isoindolinone derivatives as insecticides | BAYER CROPSCIENCE AG (DE) | 2007-02-08 | — | — | US | disclosed |
| EP-1635639-A1 | USE OF ISOINDOLINONE DERIVATIVES AS INSECTICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110149-A1 | USE OF ISOINDOLINONE DERIVATIVES AS INSECTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | HPGD 2690/4885NPSR1 2641/4885NPC1 2035/4885 |
| US-20220002231-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | PARG, PARP12, PARP15 | HPGD 152/4885NPSR1 3995/4885NPC1 2270/4885 |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | HPGD 1521/4885NPSR1 4173/4885NPC1 4797/4885 |
| US-20070031514-A1 | Use of isoindolinone derivatives as insecticides | DDT, CYP1A2, CYP1A1 | HPGD 1738/4885NPSR1 2093/4885NPC1 2304/4885 |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | BRD4, BET1, BRD3 | HPGD 2639/4885NPSR1 4842/4885NPC1 4566/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | HPGD 1511/4885NPSR1 4297/4885NPC1 4408/4885 |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | HPGD 1521/4885NPSR1 4173/4885NPC1 4797/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | HPGD 1521/4885NPSR1 4173/4885NPC1 4797/4885 |
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | HPGD 951/4885NPSR1 1606/4885NPC1 97/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | HPGD 1521/4885NPSR1 4173/4885NPC1 4797/4885 |
| US-11111232-B2 | Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, KYNU | HPGD 83/4885NPSR1 2008/4885NPC1 2330/4885 |
| US-11858879-B2 | PARG inhibitors and method of use thereof | PARG, PARP12, PARP15 | HPGD 152/4885NPSR1 3995/4885NPC1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.